Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors.
Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, Chakravarthy B, Mobley BC, Hiebert SW, Balko JM, Sanders ME, Liu PCC, Pietenpol JA.
Schafer JM, et al. Among authors: marshall cb.
Sci Transl Med. 2020 Mar 11;12(534):eaaw8275. doi: 10.1126/scitranslmed.aaw8275.
Sci Transl Med. 2020.
PMID: 32161105
Free PMC article.